Document:

Form of Settlement Agreement and Release

 EXHIBIT 4.3 
  
 SETTLEMENT AGREEMENT AND RELEASE 
  
 BY AND BETWEEN 
  
 NEOTHERAPEUTICS, INC. 
  
 AND 
  
 OPPENHEIMER WOLFF & DONNELLY LLP 
  
 November 22, 2002 

 TABLE OF CONTENTS 
  
 
	 1.
 	 	 Definitions.
 	  	 1
 
	 
	 2.
 	 	 Payment of Shares of Common Stock.
 	  	 2
 
	 
	  	 	 (a)
 	  	 Settlement Payment
 	  	 2
 
	  	 	 (b)
 	  	 The Closing
 	  	 2
 
	  	 	 (c)
 	  	 Deliveries at the Closing
 	  	 2
 
	 
	 3.
 	 	 Representations and Warranties.
 	  	 3
 
	 
	  	 	 (a)
 	  	 Representations and Warranties of the Company
 	  	 3
 
	  	 	 (b)
 	  	 Representations and Warranties of Oppenheimer Wolff & Donnelly LLP
 	  	 3
 
	 
	 4.
 	 	 Release.
 	  	 6
 
	 
	  	 	 (a)
 	  	 Oppenheimer Wolff & Donnelly LLP Release
 	  	 6
 
	  	 	 (b)
 	  	 General Release
 	  	 6
 
	  	 	 (c)
 	  	 Representations and Warranties
 	  	 6
 
	 
	 5.
 	 	 Enforcement of Release
 	  	 7
 
	 
	 6.
 	 	 Compromise
 	  	 7
 
	 
	 7.
 	 	 Advice of Counsel
 	  	 7
 
	 
	 8.
 	 	 Registration Rights
 	  	 7
 
	 
	  	 	 (a)
 	  	 Obligations of the Company
 	  	 7
 
	  	 	 (b)
 	  	 Furnish Information
 	  	 8
 
	  	 	 (c)
 	  	 Expenses of Registration
 	  	 8
 
	  	 	 (d)
 	  	 Delay of Registration
 	  	 8
 
	  	 	 (e)
 	  	 Indemnification
 	  	 8
 
	  	 	 (f)
 	  	 Reports Under Exchange Act
 	  	 11
 
	  	 	 (g)
 	  	 Assignment of Registration Rights
 	  	 12
 
	  	 	 (h)
 	  	 Termination of Registration Rights
 	  	 12
 
	  	 	 (i)
 	  	 Piggyback on Registration
 	  	 12
 
	 
	 9.
 	 	 Survival of Representations and Warranties
 	  	 12
 
	 
	 10.
 	 	 Miscellaneous.
 	  	 12
 
	 
	  	 	 (a)
 	  	 Further Assurances
 	  	 12
 
	  	 	 (b)
 	  	 Recapitalizations, Etc
 	  	 12
 
	  	 	 (c)
 	  	 Delays or Omissions; Remedies Cumulative
 	  	 12
 
	  	 	 (d)
 	  	 No Third-Party Beneficiaries
 	  	 13
 
	  	 	 (e)
 	  	 Successors and Assigns
 	  	 13
 
	  	 	 (f)
 	  	 Entire Agreement
 	  	 13
 
	  	 	 (g)
 	  	 Counterparts
 	  	 13
 
	  	 	 (h)
 	  	 Headings
 	  	 13
 

 
  

 
 -i- 

 
	 (i)
 	 	 Notices
 	  	 13
 
	 (j)
 	 	 Governing Law
 	  	 14
 
	 (k)
 	 	 Amendments
 	  	 14
 
	 (l)
 	 	 Severability
 	  	 14
 
	 (m)
 	 	 Expenses
 	  	 15
 
	 (n)
 	 	 Construction
 	  	 15
 

 
  

 
 -ii- 

 SETTLEMENT AGREEMENT AND RELEASE 
  
 This Settlement Agreement and Release (the “Agreement”) is made and entered into as of November 22, 2002, by and between NeoTherapeutics, Inc., a Delaware corporation (the
“Company”), and Oppenheimer Wolff & Donnelly LLP, a limited liability partnership, (“Oppenheimer Wolff & Donnelly LLP”). The Company and Oppenheimer Wolff & Donnelly LLP are referred to collectively
herein as the “Parties.” 
  
 WHEREAS, the Company owes payment of $318,804 to Oppenheimer Wolff
& Donnelly LLP for services performed by Oppenheimer Wolff & Donnelly LLP; 
  
 WHEREAS, the Company desires
to give and Oppenheimer Wolff & Donnelly LLP desires to receive a warrant to purchase shares of common stock of the Company in lieu of cash as satisfaction of a portion of the payment owed by the Company to Oppenheimer Wolff & Donnelly LLP.

  
 NOW, THEREFORE, in consideration of the premises and the mutual promises herein made, and in consideration of the
representations, warranties, and covenants herein contained, the Parties agree as follows. 
  
 1.  Definitions. 
  
 “Agreement” means this
agreement. 
  
 “Closing” has the meaning set forth in §2(c) below.

  
 “Closing Date” has the meaning set forth in §2(c) below. 

 
 “Common Stock” means the Company’s common stock, $.001 par value per share. 

 
 “Company” has the meaning set forth in the preface above. 
  
 “Effectiveness Date” means the 120th day following the Closing Date. 
  
 “Exchange Act” has the meaning set forth in §8(e)(i) below. 
  
 “Filing Date” means the 60th day following the Closing Date. 
  
 “Market Price” means, as of any date of determination, (i) the last reported sale price per share of the Common Stock on the business day immediately preceding the date of
determination as reported on the Nasdaq SmallCap Market, or (ii) if there is no such reported sale on the date in question, the average of the closing bid and asked quotations as so reported on the Nasdaq SmallCap Market, or (iii) if the Common
Stock is not then listed on the Nasdaq SmallCap Market, the last reported sale price per share of the Common Stock on such national securities exchange upon which the Common Stock is then listed, or (iv) if the Common Stock is not then listed on any
national securities exchange, the average of the closing bid and asked quotations in the over-the-counter market as reported by Nasdaq, or if not so reported, as reported by the National Quotations Bureau or a similar organization. In the absence of
such quotations, the 
  

  
 Board of Directors of the Company shall determine in good faith the fair market
value per share of the Common Stock, which shall for these purposes be deemed to be the Market Price, which determination shall be set forth in a certificate executed by an officer of the Company showing the facts upon which the Market Price is
based. 
  
 “Oppenheimer Wolff & Donnelly LLP” has the meaning set forth in the
preface above. 
  
 “Outstanding Debt” has the meaning set forth in §2(a) below.

  
 “Parties” has the meaning set forth in the preface above. 

 
 “person(s)” means an individual, a partnership, a corporation, an association, a joint stock
company, a trust, a joint venture, an unincorporated organization, or a governmental entity (or any department, agency, or political subdivision thereof). 
  
 “Register,” “registered,” and “registration” refer to a registration effected by preparing and filing a
registration statement or similar document in compliance with the Securities Act and the declaration or ordering of effectiveness of such registration statement or document. 
  
 “SEC” means the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act. 

 
 “Securities Act” means the Securities Act of 1933, as amended. 
  
 “Warrant” has the meaning set forth in §2(a) below. 
  
 2.  Payment of Warrants for Shares of Common Stock 
  
 (a)  Settlement Payment.    The Company agrees to issue to Oppenheimer Wolff & Donnelly LLP at the Closing a warrant to purchase up
to 161,460 shares of Common Stock at a purchase price of $0.25 per share, in substantially the form attached hereto as Exhibit A (the “Warrant”), and pay $75,000 by check, in full and complete settlement and satisfaction of the
outstanding amount of $318,804 owed by the Company to Oppenheimer Wolff & Donnelly LLP, for services provided as patent counsel and billed on invoices 640107, 642594, 642764, 645736, 645756, 649558, 653788, 658470 and 658486 (the
“Outstanding Debt”). 
  
 (b)  Additional Payment.    If the
Market Price on the Effectiveness Date is lower than $1.76, the Company will pay to the Holder, within thirty (30) days following the Effectiveness Date, an amount of cash equal to (i) the difference between $1.76 and the Market Price as determined
pursuant to Section 1(c), multiplied by (ii) 138,525. 
  
 (c)  The
Closing.    The closing of the transactions contemplated by this Agreement (the “Closing”) shall take place upon the date of the signing of this Agreement by all Parties (the “Closing Date”).

  
 (d)  Deliveries at the Closing.    At the Closing, (i) the Parties will
exchange signed copies of this Agreement and (ii) the Company will deliver to Oppenheimer Wolff & Donnelly LLP the original Warrant duly executed by an authorized officer of the Company. 
  

 
 -2- 

  
 3.  Representations and Warranties. 
  
 (a)  Representations and Warranties of the Company.    The Company represents and warrants to
Oppenheimer Wolff & Donnelly LLP that the statements contained in this §3(a) are correct and complete as of the date of this Agreement. 
  
 (i)  Authorization of Transaction.    The Company has full power and authority (including full corporate power and authority) to execute and deliver this Agreement
and to perform his or its obligations hereunder. All action of the Company necessary to authorize the execution and delivery of this Agreement and performance by the Company of all of its obligations hereunder has been taken, and this Agreement
constitutes the valid and legally binding obligation of the Company, enforceable in accordance with its terms and conditions. Except as set forth in Section 8 below, the Company need not give any notice to, make any filing with, or obtain any
authorization, consent, or approval of any government or governmental agency in order to consummate the transactions contemplated by this Agreement. 
  
 (ii)  Noncontravention.    Neither the execution and the delivery of this Agreement, nor the consummation of the
transactions contemplated hereby, will violate any constitution, statute, regulation, rule, injunction, judgment, order, decree, ruling, charge, or other restriction of any government, governmental agency, or court to which the Company is subject,
or any provision of its charter. 
  
 (iii)  Brokers’
Fees.    The Company has no liability or obligation to pay any fees or commissions to any broker, finder, or agent with respect to the transactions contemplated by this Agreement for which Oppenheimer Wolff & Donnelly LLP
could become liable or obligated. 
  
 (b) Representations and Warranties of Oppenheimer Wolff & Donnelly
LLP.    Oppenheimer Wolff & Donnelly LLP represents and warrants to the Company that the statements contained in this §3(b) are correct and complete as of the date of this Agreement. 
  
 (i)  Organization of Oppenheimer Wolff & Donnelly LLP.    Oppenheimer Wolff &
Donnelly LLP is a limited liability partnership duly organized, validly existing, and in good standing under the laws of the jurisdiction of its formation. 
  
 (ii)  Authorization of Transaction.    Oppenheimer Wolff & Donnelly LLP has full power and authority (including
full limited liability partnership power and authority) to execute and deliver this Agreement and to perform its obligations hereunder. All action of Oppenheimer Wolff & Donnelly LLP necessary to authorize the execution and delivery of this
Agreement and performance by Oppenheimer Wolff & Donnelly LLP of all of its obligations hereunder has been taken, and this Agreement constitutes the valid and legally binding obligation of Oppenheimer Wolff & Donnelly LLP, enforceable in
accordance with its terms and conditions. Oppenheimer Wolff & Donnelly LLP 
  

 
 -3- 

  
 need not give any notice to, make any filing with, or obtain any authorization,
consent, or approval of any government or governmental agency in order to consummate the transactions contemplated by this Agreement. 
  
 (iii)  Noncontravention.    Neither the execution and the delivery of this Agreement, nor the consummation of the transactions contemplated hereby, will violate any
constitution, statute, regulation, rule, injunction, judgment, order, decree, ruling, charge, or other restriction of any government, governmental agency, or court to which Oppenheimer Wolff & Donnelly LLP is subject or any provision of its
partnership agreement. 
  
 (iv)  Brokers’
Fees.    Oppenheimer Wolff & Donnelly LLP has no liability or obligation to pay any fees or commissions to any broker, finder, or agent with respect to the transactions contemplated by this Agreement for which the Company
could become liable or obligated. 
  
 (v)  Business or Financial
Expertise.    Oppenheimer Wolff & Donnelly LLP has either (i) a pre-existing personal or business relationship with the Company or any of its officers, directors or controlling persons that is of a nature and duration
which enables Oppenheimer Wolff & Donnelly LLP to be aware of the character, business acumen and general business and financial circumstances of the Company or (ii) by reason of Oppenheimer Wolff & Donnelly LLP’s business or financial
expertise or the business or financial experience of its professional advisors who are unaffiliated with and who are not compensated by the Company or any affiliate or selling agent of the Company, directly or indirectly, the capacity to protect its
own interests in connection with its acquisition of the Shares. Oppenheimer Wolff & Donnelly LLP is an “accredited investor” as defined in Rule 501 of Regulation D of the Securities Act. 
  
 (vi)  Awareness; No Distribution.    Oppenheimer Wolff & Donnelly LLP has had the
opportunity to ask questions about the Company’s business affairs and financial condition, and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Warrant and the shares of Common
Stock issuable upon exercise of the Warrant (the “Warrant Shares”). Oppenheimer Wolff & Donnelly LLP is acquiring the Warrant and the Warrant Shares for its own account for investment purposes only and not with a view to, or for
the resale in connection with, any “distribution” thereof for purposes of the Securities Act. Oppenheimer Wolff & Donnelly LLP recognizes that the Warrant and the Warrant Shares are a speculative investment involving a high degree of
risk of loss and that Oppenheimer Wolff & Donnelly LLP could lose the entire amount of its investment. Oppenheimer Wolff & Donnelly LLP is able to bear the economic risk of this investment and at the present time could afford a complete loss
of this investment. 
  
 (vii)  No Registration.    Oppenheimer
Wolff & Donnelly LLP understands that the Warrant and the Warrant Shares will be issued without registration under the Shares Act and without qualification and/or registration 

 
 -4- 

  
 under applicable state securities laws (“Blue Sky Laws”) in
reliance upon specific exemptions therefrom, which exemptions depend upon, among other things, the bona fide nature of its investment intent as expressed herein. In this connection, Oppenheimer Wolff & Donnelly LLP understands that, in the view
of the SEC, the statutory basis for such exemption may be unavailable if its representations were predicated solely upon a present intention to hold the Warrant and the Warrant Shares for the minimum capital gains period specified under tax
statutes, for a deferred sale, for or until an increase or decrease in the market price of the Common Stock, or for a period of one year or any other fixed period in the future. 
  
 (viii)  Legend.    Oppenheimer Wolff & Donnelly LLP further understands that the Warrant and the Warrant Shares
must be held indefinitely unless subsequently registered and/or qualified under the Securities Act and under the Blue Sky Laws or unless an exemption from registration and/or qualification is otherwise available. In addition, Oppenheimer Wolff &
Donnelly LLP understands that the Warrant and any certificate evidencing the Warrant Shares will be imprinted with a legend in substantially the form as follows which prohibits the transfer of the Warrant and the Warrant Shares unless they are
registered and/or qualified or such registration and/or qualification is not required in the opinion of counsel for Oppenheimer Wolff & Donnelly LLP. 
  
 THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER SECURITIES ACT OF
1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS
THEREUNDER AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. 
  
 (ix)  Rule 144.    Oppenheimer Wolff & Donnelly LLP is aware of the provisions of Rule 144, promulgated under the Securities Act, which, in substance, permits limited public resale of
“restricted securities” acquired, directly or indirectly, from the issuer thereof (or from an affiliate of such issuer), in a non-public offering subject to the satisfaction of certain conditions. Oppenheimer Wolff & Donnelly LLP
understands that the Warrant and the Warrant Shares constitute “restricted securities” for the purposes of Rule 144. 
  
 (x)  No Public Market.    Oppenheimer Wolff & Donnelly LLP further understands that at the time it wishes to sell the Warrant or the Warrant Shares there may be
no public market upon which to make such a sale. 
  
 (xi)  Risk.    Oppenheimer Wolff & Donnelly LLP further understands that in the event all of the requirements of Rule 144 are not satisfied, registration under the Securities Act, compliance
with Regulation A, or some other 
  

 
 -5- 

  
  
 registration exemption will be required;
and that, notwithstanding the fact that Rule 144 is not exclusive, the Staff of the SEC has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rule 144
will have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk.

  
 4.  Release. 
  
 (a)  Oppenheimer Wolff & Donnelly LLP Release.    For good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, Oppenheimer Wolff & Donnelly LLP and its heirs, successors and assigns do hereby release and forever discharge the Company, together with its affiliates, employees, agents, representatives, partners, shareholders, officers
and directors, successors and assigns (collectively, the “Company Parties”) of and from all common law and statutory claims, demands, damages, debts, losses, actions and causes of action, suits, rights, liabilities, contracts,
duties and obligations, of any kind and nature whatsoever, whether known or unknown, accrued or to accrue, contingent or liquidated (collectively “Claims”), that Oppenheimer Wolff & Donnelly LLP had, now has or may have against
any Company Parties, arising from or in connection with the Outstanding Debt. 
  
 (b)  General
Release.    It is the intention of Oppenheimer Wolff & Donnelly LLP in providing this release that the same shall be effective as a bar to each and every claim, demand and cause of action hereinabove specified; and in
furtherance of this intention, Oppenheimer Wolff & Donnelly LLP hereby expressly waives any and all rights and benefits conferred upon it by the provisions of Section 1542 of the California Civil Code and expressly agrees that the above release
is intended to and does extend to and cover claims of the type referred to in said Section 1542, which reads as follows: 
  

	    
	 
	“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR EXPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH
IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.” 
 

  
 Oppenheimer Wolff & Donnelly LLP expressly consents that the above release shall be given full force and effect according to each and all of its express terms and provisions, including as well those relating to the unknown and
unsuspected claims, demands and causes of action hereinabove specified. 
  
 (c)  Representations and
Warranties.    Oppenheimer Wolff & Donnelly LLP hereby represents and warrants to the Company that it is the current legal and beneficial owner of all Claims released hereby and has not assigned, pledged or contracted to
assign or pledge any such Claim to any other person. Oppenheimer Wolff & Donnelly LLP agrees to indemnify, defend and hold harmless the Company from and against and in respect of any claims, demands, 
  

 
 -6- 

  
 losses, costs, expenses, obligations, liabilities or damages asserted against the Company by Oppenheimer
Wolff & Donnelly LLP in respect of any Claim. 
  
 5.  Enforcement of
Release.    The release set forth in Section 4 above may be pleaded as the full and complete defense to, and as a basis for an injunction against, any action, suit or other proceeding which may be instituted, prosecuted or
attempted with respect to any Claim. If Oppenheimer Wolff & Donnelly LLP brings an action in respect of any Claim released hereby, the Company shall be entitled to recover its costs and expenses, including court costs and attorneys’ fees,
if any, incurred in connection with such suit, including appeals therefrom, whether or not such action is prosecuted to final judgment. 
  
 6.  Compromise.    The Parties hereto acknowledge and agree that this Agreement is entered into as a compromise settlement which is not in any respect or for any purpose to be deemed or
construed as an admission or concession of any liability whatsoever on the part of any party hereto. 
  
 7.  Advice of Counsel.    The Parties have carefully and completely read this Agreement, have not relied upon any representations or warranties of the other party (except as set forth in this
Agreement) in signing it, have had an opportunity to review it with their attorneys, and are satisfied they understand its terms. 
  
 8.  Registration Rights. 
  
 (a)  Obligations of the
Company.    On or prior to the Filing Date, the Company shall, as expeditiously as reasonably possible: 
  
 (i)  Prepare and file with the SEC a registration statement with respect to the resale of the Warrant Shares and use commercially reasonable efforts to cause such registration statement to
become effective as promptly as possible after the filing thereof, but in any event prior to the Effectiveness Date. 
  
 (ii)  Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the
provisions of the Securities Act. 
  
 (iii)  Furnish to Oppenheimer Wolff & Donnelly
LLP such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of the Shares.

  
 (iv)  Use commercially reasonable efforts to register and qualify the securities
covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by Oppenheimer Wolff & Donnelly LLP, provided that the Company shall not be required in connection
therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 
  

 
 -7- 

  
 (v)  Promptly notify Oppenheimer Wolff & Donnelly
LLP at any time when the Company becomes aware of the happening of any event as a result of which the registration statement or the prospectus included in such registration statement or any supplement to the prospectus (as then in effect) contains
any untrue statement of a material fact or omits to state a material fact necessary to make the statements there in (in the case of the prospectus, in light of the circumstances under which they were made) not misleading or, if for any other reason
it shall be necessary during such time period to amend or supplement the registration statement or the prospectus in order to comply with the Securities Act, whereupon, in either case, Oppenheimer Wolff & Donnelly LLP shall immediately cease to
use such registration statement or prospectus for any purpose and, as promptly as practicable thereafter, the Company shall prepare and file with the SEC, and furnish without charge to Oppenheimer Wolff & Donnelly LLP a supplement or amendment
to such registration statement or prospectus which will correct such statement or omission or effect such compliance and such copies thereof as Oppenheimer Wolff & Donnelly LLP may reasonably request. 
  
 (vi)  Use commercially reasonable efforts to cause all the Warrant Shares registered pursuant hereunder to be
listed on each securities exchange or market on which similar securities issued by the Company are then listed or traded, if applicable. 
  
 (b)  Furnish Information.    It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 8 with respect to the Warrant Shares that
Oppenheimer Wolff & Donnelly LLP shall furnish to the Company such information regarding itself, the Warrant Shares held by it, and the intended method of disposition of such securities as shall be required to effect the registration of the
Warrant Shares. 
  
 (c)  Expenses of Registration.    All expenses including
without limitation all registration, filing and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for Oppenheimer Wolff & Donnelly
LLP, shall be borne by the Company. 
  
 (d)  Delay of
Registration.    Oppenheimer Wolff & Donnelly LLP shall not have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with
respect to the interpretation or implementation of this Section 8. 
  
 (e)  Indemnification.    In the event the Warrant Shares are included in a registration statement under this Section 8: 
  
 (i)  Indemnification by the Company.    To the extent permitted by law, the Company will indemnify and hold harmless
Oppenheimer Wolff & Donnelly LLP, any underwriter (as defined in the Securities Act) for Oppenheimer Wolff & Donnelly LLP and each person, if any, who controls Oppenheimer Wolff & Donnelly LLP or underwriter within the meaning of the
Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), against any 
  

 
 -8- 

 losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the
Exchange Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a
“Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or
supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the
Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law; and the Company will pay to Oppenheimer Wolff & Donnelly LLP, underwriter or
controlling person, as incurred, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement
contained in this Section 8(e)(i) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably
withheld), nor shall the Company be liable to Oppenheimer Wolff & Donnelly LLP, underwriter or controlling person for any such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Violation (x) which
occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by Oppenheimer Wolff & Donnelly LLP, underwriter or controlling person or (y) which occurs in any preliminary
prospectus if a final, amended or supplemental prospectus which corrects such Violation is delivered by the Company to such person at or prior to the written confirmation of the sale giving rise to such loss, claim, damage, liability, or action.

  
 (ii)  Indemnification by Oppenheimer Wolff & Donnelly
LLP.    To the extent permitted by law, Oppenheimer Wolff & Donnelly LLP will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if
any, who controls the Company within the meaning of the Securities Act, any underwriter and any controlling person of any such underwriter or Oppenheimer Wolff & Donnelly LLP, against any losses, claims, damages, or liabilities (joint or
several) to which any of the foregoing persons may become subject, under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are
based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by Oppenheimer Wolff & Donnelly LLP expressly for use in connection
with such registration statement; and Oppenheimer Wolff & Donnelly LLP will pay, as incurred, any legal or other expenses reasonably incurred by any person intended to be indemnified pursuant to this Section 8(e)(ii), in connection with

  

 
 -9- 

 investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the
indemnity agreement contained in this Section 8(e)(ii) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of Oppenheimer Wolff & Donnelly LLP,
which consent shall not be unreasonably withheld; provided, that in no event shall any indemnification by Oppenheimer Wolff & Donnelly LLP under this Section 8(e)(ii) exceed the net proceeds from the offering received by Oppenheimer Wolff
& Donnelly LLP, except in the case of willful fraud by Oppenheimer Wolff & Donnelly LLP. 
  
 (iii)  Procedures.    Promptly after receipt by an indemnified party under this Section 8(e) of notice of the commencement of any action (including any governmental action), such indemnified party
will, if a claim in respect thereof is to be made against any indemnifying party under this Section 8(e), deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate
in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified
party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the reasonable fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such
proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if materially prejudicial to its ability to defend such action, shall relieve such indemnifying party of any
liability to the indemnified party under this Section 8(e), but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section
8(e). No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term
thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. The indemnity agreements contained in this Section 8(e) shall not apply to amounts paid in settlement
of any loss, claim, damage, liability or action if such settlement is effected without the consent of the indemnifying party, such consent not to be unreasonably withheld. 
  
 (iv)  Contribution.    If the indemnification provided for in this Section 8(e) is held by a court of competent
jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the
amount paid or payable by 
  

 
 -10- 

 such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is
appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as
any other relevant equitable considerations; provided, that in no event shall any contribution by Oppenheimer Wolff & Donnelly LLP under this Section 8(e)(iv) exceed the net proceeds from the offering received by such Oppenheimer Wolff
& Donnelly LLP, except in the case of willful fraud by Oppenheimer Wolff & Donnelly LLP. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and
opportunity to correct or prevent such statement or omission. 
  
 (v)  Survival.    The obligations of the Company and Oppenheimer Wolff & Donnelly LLP under this Section 8(e) shall survive the completion of any offering of the Shares in a registration
statement under this Section 8, and otherwise. 
  
 (f)  Reports Under Exchange
Act.    With a view to making available to Oppenheimer Wolff & Donnelly LLP the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the SEC that may at any time permit Oppenheimer
Wolff & Donnelly LLP to sell securities of the Company to the public without registration, the Company agrees to: 
  
 (i)  make and keep public information available, in accordance with SEC Rule 144, at all times after the effective date of the first registration statement filed by the Company for the offering of its securities to
the general public so long as the Company remains subject to the periodic reporting requirements under Sections 13 or 15(d) of the Exchange Act; 
  
 (ii)  file with the SEC in a timely manner all reports and other documents as may be required of the Company under the Securities Act and the Exchange Act; and 
  
 (iii)  furnish to Oppenheimer Wolff & Donnelly LLP, so long as Oppenheimer Wolff & Donnelly LLP owns the
Warrant or any Warrant Shares, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144, the Securities Act and the Exchange Act (at any time after it has become subject to
such reporting requirements), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing
Oppenheimer Wolff & Donnelly LLP of any rule or regulation of the SEC which 
  

 
 -11- 

  
  
 permits the selling of any such
securities without registration or pursuant to such form. 
  
 (g)  Assignment of
Registration Rights.    The rights granted Oppenheimer Wolff & Donnelly LLP under Section 8 may not be assigned to a transferee or assignee of Warrant or the Warrant Shares without the prior written consent of the
Company, except that such rights may be freely transferred to any party controlling, controlled by or under common control with Oppenheimer Wolff & Donnelly LLP without such consent; provided, that the Company is provided with prompt
notice of the name and address of such transferee and such transferee agrees in writing to be bound by the provisions of this Agreement. 
  
 (h)  Termination of Registration Rights.    Oppenheimer Wolff & Donnelly LLP shall not be entitled to exercise any registration right provided for in this
Section 8 after such time as Rule 144(k) or another similar exemption under the Securities Act is available for the sale of all of the Shares without limitation as to volume or manner of sale. 
  

(i)  Piggyback on Registration.    The Company may include shares of Common Stock held by other stockholders of
the Company in the registration statement filed pursuant to this Section 8. 
  
 9.  Survival of
Representations and Warranties.    All of the representations and warranties of the Parties contained in this Agreement shall survive the Closing hereunder (even if the damaged party knew or had reason to know of any
misrepresentation or breach of warranty or covenant at the time of Closing) and continue in full force and effect forever thereafter (subject to any applicable statutes of limitations). 
  
 10.  Miscellaneous. 
  
 (a)  Further Assurances.    The Company and Oppenheimer Wolff & Donnelly LLP shall deliver or cause to be delivered to the other party on the Closing Date and at such other times and places as
shall be reasonably agreed to, such additional instruments as any of the other party may reasonably request for the purposes of carrying out this Agreement. 
  
 (b)  Recapitalizations, Etc.    The provisions of this Agreement shall apply, to the full extent set forth herein with respect to the Warrant and to the Warrant
Shares, to any and all shares of capital stock of the Company or any capital stock, partnership or member units or any other security evidencing ownership interests in any successor or assign of the Company (whether by merger, consolidation, sale of
assets or otherwise) that may be issued in respect of, in exchange for, or in substitution of the Warrant or the Warrant Shares by reason of any stock dividend, split, combination, recapitalization, liquidation, reclassification, merger,
consolidation or otherwise. 
  
 (c)  Delays or Omissions; Remedies
Cumulative.    No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or
remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default 

 
 -12- 

 thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or
thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement,
must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

 
 (d)  No Third-Party Beneficiaries.    This Agreement shall not confer any rights or
remedies upon any person other than the Parties and their respective successors and permitted assigns. 
  
 (e)  Successors and Assigns.    This Agreement shall be binding upon and inure to the benefit of and be enforceable by the Parties and their respective successors and assigns. Notwithstanding the
foregoing, neither this Agreement nor any rights hereunder may be assigned by any party without the prior written consent of the other party. 
  
 (f)  Entire Agreement.    This Agreement (including the documents referred to herein) constitutes the entire agreement among the Parties and supersedes any prior
understandings, agreements, or representations by or among the Parties, written or oral, to the extent they related in any way to the subject matter hereof. 
  
 (g)  Counterparts.    This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together will
constitute one and the same instrument. 
  
 (h)  Headings.    The section
headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. 
  
 (i)  Notices.    All notices, requests, demands, claims, and other communications hereunder will be in writing. Any notice, request, demand, claim, or other
communication hereunder shall be deemed duly given if (and then two business days after) it is sent by registered or certified mail, return receipt requested, postage prepaid, and addressed to the intended recipient as set forth below: 

 
 If to Oppenheimer Wolff & Donnelly LLP: Copy to: 
  
 Oppenheimer Wolff & Donnelly LLP 
 840 Newport Center Drive, Suite 700 
 Newport Beach, CA 92660 
 Attn: David Perry 
  
 Fax: (949) 823-6100 
  

 
 -13- 

  
 If to the Company: Copy to: 
  
 NeoTherapeutics, Inc. 
 157 Technology Drive 
 Irvine, CA 92618 
 Attn: John McManus 
 Fax: (949) 788-6706 
  
 with a copy to: 
  
 Latham & Watkins 
 650 Town Center Drive, Suite 2000 
 Costa Mesa, CA 92626 
 Attn: Alan W. Pettis,
Esq. 
 Fax: (714) 755-8290 
  
 Either party may send any notice, request, demand, claim, or other communication hereunder to the intended recipient at the address set forth above using any other means (including personal delivery, expedited courier, messenger
service, telecopy, telex, ordinary mail, or electronic mail), but no such notice, request, demand, claim, or other communication shall be deemed to have been duly given unless and until it actually is received by the intended recipient. Either party
may change the address to which notices, requests, demands, claims, and other communications hereunder are to be delivered by giving the other party notice in the manner herein set forth. 
  
 (j)  Governing Law.    All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be
governed by and construed and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of law thereof. The Company and Oppenheimer Wolff & Donnelly LLP hereby irrevocably submit to
the exclusive jurisdiction of the state and federal courts sitting in Orange County, California, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, or that such suit, action or proceeding is improper. Each of the Company and
Oppenheimer Wolff & Donnelly LLP hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by receiving a copy thereof sent to the Company at the address in effect for
notices to it under this instrument and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner
permitted by law. 
  
 (k)  Amendments.    No amendment of any provision of this
Agreement shall be valid unless the same shall be in writing and signed by Oppenheimer Wolff & Donnelly LLP and the Company. 
  
 (l)  Severability.    Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of 

 
 -14- 

  
 the remaining terms and provisions hereof or the validity or enforceability of the offending term or
provision in any other situation or in any other jurisdiction. 
  
 (m)  Expenses.    Except as set forth in Section 8 above, each party will bear his or its own costs and expenses (including legal fees and expenses) incurred in connection with this Agreement and
the transactions contemplated hereby. 
  
 (n)  Construction.    Any reference to
any federal, state, local, or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. The word “including” shall mean including without limitation.
The Parties intend that each representation, warranty, and covenant contained herein shall have independent significance. If any party has breached any representation, warranty, or covenant contained herein in any respect, the fact that there exists
another representation, warranty, or covenant relating to the same subject matter (regardless of the relative levels of specificity) which the party has not breached shall not detract from or mitigate the fact that the party is in breach of the
first representation, warranty, or covenant. 
  
 ***** 

 
 -15- 

  
 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the
date first above written. 
  
 
	 NEOTHERAPEUTICS, INC.
 
	 
	 By:
 	 	 /s/    JOHN L.
MCMANUS      
 

	 Title:
 	 	 V.P. Strategic Planning & Finance
 

 
  
 
	 OPPENHEIMER WOLFF & DONNELLY LLP
 
	 
	 By:
 	 	 /s/    DAVID J.
PERRY        
 

	 Title:
 	 	 Orange County Office Managing Partner
 

 
  

 
 -16- 

  
 EXHIBIT A 
  
 FORM OF WARRANTWarrant issues by Registrant to Oppenheimer

  
 EXHIBIT 4.4 
  
 THIS WARRANT HAS BEEN ACQUIRED FOR INVESTMENT AND HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE. THIS WARRANT
MAY NOT BE SOLD OR TRANSFERRED, EXCEPT UPON SUCH REGISTRATION OR UPON DELIVERY TO MAKER OF AN OPINION OF COUNSEL SATISFACTORY TO MAKER THAT REGISTRATION IS NOT REQUIRED FOR SUCH SALE OR TRANSFER. 
  

	 Dated: January 1, 2003
 	 	 Number NEOT076
 

 
  
 NEOTHERAPEUTICS, INC. 
  
 Warrant for the Purchase of Shares of Common Stock 
  
 161,460 Shares 
  
 FOR VALUE RECEIVED, NeoTherapeutics,
Inc., a Delaware corporation (the “Company”), hereby certifies that Oppenheimer Wolff & Donnelly LLP or its permitted assigns, is entitled to purchase from the Company, at any time or from time to time commencing on January
1, 2003 and prior to 5:00 P.M., Pacific time, on December 31, 2007, One Hundred Sixty-One Thousand Four Hundred Sixty (161,460) fully paid and non-assessable shares of the common stock, $.001 par value per share, of the Company for an aggregate
purchase price of $40,365 (computed on the basis of $0.25 per share). Hereinafter, (i) said common stock, together with any other equity securities which may be issued by the Company with respect thereto or in substitution therefor, is
referred to as the “Common Stock,” (ii) the shares of the Common Stock purchasable hereunder or under any other Warrant (as hereinafter defined) are referred to individually as a “Warrant Share” and collectively as the
“Warrant Shares,” (iii) the aggregate purchase price payable for the Warrant Shares hereunder is referred to as the “Aggregate Warrant Price,” (iv) the price payable for each of the Warrant Shares hereunder is referred to as the
“Per Share Warrant Price,” (v) this Warrant, all similar Warrants issued on the date hereof and all Warrants hereafter issued in exchange or substitution for this Warrant or such similar Warrants are referred to as the
“Warrants”, and (vi) the holder of this Warrant is referred to as the “Holder” and the holder of this Warrant and all other Warrants or Warrant Shares issued upon the exercise of any Warrant are referred to as the
“Holders.” The Aggregate Warrant Price is not subject to adjustment. The Per Share Warrant Price is subject to adjustment as hereinafter provided, and in the event of any such adjustment, the number of Warrant Shares shall be adjusted to
equal the number determined by dividing the Aggregate Warrant Price by the Per Share Warrant Price in effect immediately after such adjustment. 
  
 This Warrant is issued pursuant to that certain Settlement Agreement and Release, dated November 22, 2002, between the Company and the Holder (the “Settlement Agreement”). 

 
 1.  Exercise of Warrant. 
  
 (a)  This Warrant may be exercised in whole at any time or in part from time to time, during the period commencing on January 1, 2003 and ending
prior to 5:00 P.M., Pacific time, on December 31, 2007 (such period, the “Exercise Period”), by the Holder by the surrender of this Warrant (with the subscription form at the end of this Warrant duly executed) at the address set forth in
Section 9(a) hereof, together with proper payment of 

  
 the Aggregate Warrant Price, or the proportionate part thereof if this Warrant is
exercised in part. Payment for Warrant Shares shall be made by certified or official bank check payable to the order of the Company. If this Warrant is exercised in part, this Warrant must be exercised for a number of whole shares of the Common
Stock, and the Holder is entitled to receive a new Warrant covering the Warrant Shares in respect of which this Warrant has not been exercised and setting forth the proportionate part of the Aggregate Warrant Price applicable to such Warrant Shares.
Upon such exercise and surrender of this Warrant, the Company will (i) issue a certificate or certificates in the name of the Holder for the largest number of whole shares of the Common Stock to which the Holder shall be entitled and, if this
Warrant is exercised in whole, in lieu of any fractional share of the Common Stock to which the Holder shall be entitled, pay to the Holder cash in an amount equal to the fair value of such fractional share (determined in such reasonable manner as
the Board of Directors of the Company shall determine) and (ii) deliver the other securities and properties receivable upon the exercise of this Warrant, or the proportionate part thereof if this Warrant is exercised in part, pursuant to the
provisions of this Warrant. 
  
 (b)  In lieu of exercising this Warrant in the manner set
forth in Section 1(a) above, this Warrant may be exercised in whole at any time or in part from time to time during the Exercise Period, by the Holder by surrendering the Warrant at the address set forth in Section 9(a) hereof, without payment of
any other consideration, commission or remuneration, together with the subscription form at the end of this Warrant, duly executed. The number of shares of the Common Stock to be issued by the Company shall be calculated using the following formula:

  
 
	 X=
 	  	 Y(A-B)
 

	  	  	 A
 

 
  
 
	                         Where
 	  	 X=
 	  	 the number of shares of the Common Stock to be issued to the Holder
 
	 
	  	  	 Y=
 	  	 the number of shares of the Common Stock purchasable under this Warrant or, if this Warrant is being exercised in part, under the portion of the Warrant being
exercised (at the date of the surrender of this Warrant and the subscription form)
 
	 
	  	  	 A=
 	  	 the Market Price (at the date of the surrender of this Warrant and the subscription form)
 
	 
	  	  	 B=
 	  	 the Per Share Warrant Price (as adjusted to the date of the surrender of this Warrant and the subscription form)
 

 
  
 If this Warrant is exercised in part pursuant to this Section 1(b),
this Warrant must be exercised for a number of whole shares of the Common Stock, and the Holder is entitled to receive a new Warrant covering the Warrant Shares in respect of which this Warrant has not been exercised and setting forth the
proportionate part of the Aggregate Warrant Price applicable to such Warrant Shares. Upon such exercise and surrender of this Warrant, the Company will (i) 

 
 -2- 

  
 issue a certificate or certificates in the name of the Holder for the largest number of whole shares of
the Common Stock to which the Holder shall be entitled and, if this Warrant is exercised in whole, in lieu of any fractional share of the Common Stock to which the Holder shall be entitled, pay cash equal to the fair value of such fractional share
(determined in such reasonable manner as the Board of Directors of the Company shall determine) and (ii) deliver the other securities and properties receivable upon the exercise of this Warrant, or the proportionate part thereof if this Warrant is
exercised in part, pursuant to the provisions of this Warrant. 
  
 (c)  The market price of
a share of the Common Stock (the “Market Price”) on any date of determination shall be (i) the last reported sale price per share of the Common Stock on the business day immediately preceding the date of determination as reported on the
Nasdaq SmallCap Market, or (ii) if there is no such reported sale on the date in question, the average of the closing bid and asked quotations as so reported on the Nasdaq SmallCap Market, or (iii) if the Common Stock is not then listed on the
Nasdaq SmallCap Market, the last reported sale price per share of the Common Stock on such national securities exchange upon which the Common Stock is then listed, or (iv) if the Common Stock is not then listed on any national securities exchange,
the average of the closing bid and asked quotations in the over-the-counter market as reported by Nasdaq, or if not so reported, as reported by the National Quotations Bureau or a similar organization. In the absence of such quotations, the Board of
Directors of the Company shall determine in good faith the fair market value per share of the Common Stock, which shall for these purposes be deemed to be the Market Price, which determination shall be set forth in a certificate executed by an
officer of the Company showing the facts upon which the Market Price is based. 
  
 (d)  For
purposes of determining the number of Warrant Shares issuable to the Holder pursuant to Section 1(b) hereof, in no event will the Market Price be deemed to be less than $1.76, notwithstanding the provisions of Section 1(c) hereof (so that the
minimum number of Warrant Shares issuable pursuant to Section 1(b) will in no event be less than 138,525 Warrant Shares). 
  
 2.  Reservation of Warrant Shares, Listing.    The Company agrees that, prior to the expiration of this Warrant, the Company will at all times (a) have authorized and in reserve, and will keep
available, solely for issuance or delivery upon the exercise of this Warrant, the shares of the Common Stock and other securities and properties as from time to time shall be receivable upon the exercise of this Warrant, free and clear of all
restrictions on sale or transfer and free and clear of all preemptive rights and rights of first refusal and (b) use its best efforts to keep the shares of the Common Stock receivable upon the exercise of this Warrant authorized for listing on the
Nasdaq SmallCap Market, or similar national securities exchange, upon notice of issuance. 
  
 3.  Protection Against Dilution. 
  
 (a)  If, at any time
or from time to time after the date of this Warrant, the Company shall issue or distribute to the holders of shares of the Common Stock (i) securities, other than shares of the Common Stock, or (ii) property, other than cash, without payment
therefor, with respect to the Common Stock, then, and in each such case, the Holder, upon the exercise of this Warrant, shall be entitled to receive the securities and property which the Holder 
  

 
 -3- 

  
 would hold on the date of such exercise if, on the date of this Warrant, the
Holder had been the holder of record of the number of shares of the Common Stock subscribed for upon such exercise and, during the period from the date of this Warrant to and including the date of such exercise, had retained such shares and the
securities and properties receivable by the Holder during such period. Notice of each such distribution shall be forthwith mailed to the Holder. 
  
 (b)  If, at any time or from time to time after the date of this Warrant, the Company shall (i) pay a dividend or make a distribution on its capital stock in shares of the Common Stock, (ii)
subdivide its outstanding shares of the Common Stock into a greater number of shares, (iii) combine its outstanding shares of the Common Stock into a smaller number of shares or (iv) issue by reclassification of the Common Stock any shares of
capital stock of the Company, the Per Share Warrant Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding before such event and the denominator
shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding after such event. Upon each such adjustment of the Per Share Warrant Price pursuant to this Section 3(b), the Holder shall thereafter during the Exercise
Period be entitled to purchase, at the Per Share Warrant Price resulting from such adjustment, the number of Warrant Shares obtained by multiplying the Per Share Warrant Price in effect immediately prior to such adjustment by the number of Warrant
Shares issuable upon exercise of this Warrant immediately prior to such adjustment and dividing the product thereof by the Per Share Warrant Price resulting from such adjustment. An adjustment made pursuant to this Section 3(b) shall become
effective immediately after the record date in the case of a dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification. 
  
 (c)  In case of any consolidation or merger to which the Company is a party other than a merger or consolidation
in which the Company is the continuing corporation, or in case of any sale or conveyance to another entity of the property of the Company as an entirety or substantially as an entirety, or in the case of any statutory exchange of securities with
another entity (including any exchange effected in connection with a merger of another corporation with the Company), the Holder of this Warrant shall have the right thereafter to receive on the exercise of this Warrant the kind and amount of
securities, cash or other property which the Holder would have owned or have been entitled to receive immediately after such consolidation, merger, statutory exchange, sale or conveyance had this Warrant been exercised immediately prior to the
effective date of such consolidation, merger, statutory exchange, sale or conveyance and, in any such case, if necessary, appropriate adjustment shall be made in the application of the provisions set forth in this Section 3 with respect to the
rights and interests thereafter of the Holder of this Warrant to the end that the provisions set forth in this Section 3 shall thereafter correspondingly be made applicable, as nearly as may reasonably be, in relation to any shares of stock or other
securities or property thereafter deliverable on the exercise of this Warrant. The above provisions of this Section 3(c) shall similarly apply to successive consolidations, mergers, statutory exchanges, sales or conveyances. The issuer of any shares
of stock or other securities or property thereafter deliverable on the exercise of this Warrant shall be responsible for all of the agreements and obligations of the Company hereunder. Notice of any such consolidation, merger, statutory exchange,
sale or conveyance and of said provisions so proposed to be made, shall be mailed to the Holders of the Warrants not less than 30 days prior to such event. A sale of all or substantially all of the assets of the Company for a consideration

 
 -4- 

 consisting primarily of securities shall be deemed a consolidation or merger for the foregoing purposes. 

 
 (d)  No adjustment in the Per Share Warrant Price shall be required unless such adjustment would
require an increase or decrease of at least $0.05 per share of the Common Stock; provided, however, that any adjustments which by reason of this Section 3(d) are not required to be made shall be carried forward and taken into account
in any subsequent adjustment; provided further, however, that adjustments shall be required and made in accordance with the provisions of this Section 3 (other than this Section 3(d)) not later than such time as may be required
in order to preserve the tax-free nature of a distribution to the Holder of this Warrant or the Common Stock issuable upon exercise hereof. All calculations under this Section 3 shall be made to the nearest cent or to the nearest 1/100th of a share,
as the case may be. Anything in this Section 3 to the contrary notwithstanding, the Company shall be entitled to make such reductions in the Per Share Warrant Price, in addition to those required by this Section 3, as it in its discretion shall deem
to be advisable in order that any stock dividend, subdivision of shares or distribution of rights to purchase stock or securities convertible or exchangeable for stock hereafter made by the Company to its stockholders shall not be taxable.

  
 (e)  Whenever the Per Share Warrant Price is adjusted as provided in this Section 3 and
upon any modification of the rights of a Holder of Warrants in accordance with this Section 3, the Company shall promptly prepare a notice (the “Adjustment Notice”), which shall be certified by the Company’s Chief Executive Officer to
be true and correct. The Adjustment Notice shall set forth the Per Share Warrant Price and the number of Warrant Shares after such adjustment or the effect of such modification, a brief statement of the facts requiring such adjustment or
modification and the manner of computing the same, and copies of such notice shall be mailed to the Holders of the Warrants not later than thirty (30) days following the occurrence of the event giving rise to the adjustment. 
  
 (f)  If the Board of Directors of the Company shall (1) declare any dividend or other distribution with respect
to the Common Stock, other than a cash dividend payable otherwise than out of earnings or earned surplus, (ii) offer to the holders of shares of the Common Stock any additional shares of the Common Stock, any securities convertible into or
exercisable for shares of the Common Stock or any rights to subscribe thereto or (iii) propose a dissolution, liquidation or winding up of the Company, the Company shall mail notice thereof to the Holders of the Warrants not less than 15 days prior
to the record date fixed for determining stockholders entitled to participate in such dividend, distribution, offer or subscription right or to vote on such dissolution, liquidation or winding up. 
  
 (g)  If, as a result of an adjustment made pursuant to this Section 3, the Holder of any Warrant thereafter
surrendered for exercise shall become entitled to receive shares of two or more classes of capital stock or shares of the Common Stock and other capital stock of the Company, the Board of Directors of the Company (whose determination shall be
conclusive and shall be described in a written notice to the Holder of any Warrant promptly after such adjustment) shall determine the allocation of the adjusted Per Share Warrant Price between or among shares or such classes of capital stock or
shares of the Common Stock and other capital stock and any subsequent adjustments made pursuant to this Section 3 shall apply equally to each such resulting class of capital stock. 

 
 -5- 

  
 4.  Fully Paid Stock; Taxes.    The Company
agrees that the shares of the Common Stock represented by each and every certificate for Warrant Shares delivered on the exercise of this Warrant shall, at the time of such delivery, be validly issued and outstanding, fully paid and nonassessable,
and not subject to preemptive rights, rights of first refusal or other contractual rights to purchase securities of the Company, and the Company will take all such actions as may be necessary to assure that the par value or stated value, if any, per
share of the Common Stock is at all times equal to or less than the then Per Share Warrant Price. The Company further covenants and agrees that it will pay, when due and payable, any and all federal and state stamp, original issue or similar taxes
which may be payable in respect of the issue of any Warrant Share or certificate therefor. 
  
 5.  Registration Under Securities Act of 1933. 
  
 The Company will prepare and file
with the U.S. Securities and Exchange Commission a registration statement under the Securities Act of 1933, as amended, with respect to the resale of the Warrant Shares in accordance with the terms of Settlement Agreement. 
  
 6.  Limited Transferability.    This Warrant may not be sold, transferred, assigned or hypothecated
by the Holder except in compliance with the provisions of the Securities Act and any applicable state securities laws. The Company may treat the registered Holder of this Warrant as he or it appears on the Company’s books at any time as the
Holder for all purposes. The Company shall permit any Holder of a Warrant or his or its duly authorized attorney, upon written request during ordinary business hours, to inspect and copy or make extracts from its books showing the registered holders
of Warrants. All Warrants issued upon the transfer or assignment of this Warrant will be dated the same date as this Warrant, and all rights of the Holder thereof shall be identical to those of the Holder of this Warrant. 
  
 7.  Loss, etc., of Warrant.    Upon receipt of evidence satisfactory to the Company of the loss,
theft, destruction or mutilation of this Warrant, and of indemnity reasonably satisfactory to the Company, if lost, stolen or destroyed, and upon surrender and cancellation of this Warrant, if mutilated, the Company shall execute and deliver to the
Holder a new Warrant of like date, tenor and denomination. 
  
 8.  Warrant Holder Not
Stockholder.    Except as otherwise provided herein, this Warrant does not confer upon the Holder any right to vote or to consent to or receive notice as a stockholder of the Company, as such, in respect of any matters
whatsoever, or any other rights or liabilities as a stockholder, prior to the exercise hereof. 
  
 9.  Communication.    No notice or other communication under this Warrant shall be effective unless, but any notice or other communication shall be effective and shall be deemed to have been given
if, the same is in writing and is mailed by first-class mail, postage prepaid, addressed to: 
  
 (a)  the Company at 157 Technology Drive, Irvine, California, 92618, Attention: John McManus, or such other address as the Company has designated in writing to the Holder, or 
  

 
 -6- 

  
 (b)  the Holder at Oppenheimer Wolff & Donnelly
LLP, Plaza VII, Suite 3300, 45 South Seventh Street, Minneapolis, Minnesota 55402, Attention: Mr. Howie Booth, or such other address as the Holder has designated in writing to the Company. 
  
 10.  Headings.    The headings of this Warrant have been inserted as a matter of convenience and shall not affect the construction
hereof. 
  
 11.  Applicable Law.    This Warrant shall be governed by and
construed in accordance with the law of the State of Delaware without giving effect to the principles of conflicts of law thereof. 
  
 IN WITNESS WHEREOF, NeoTherapeutics, Inc. has caused this Warrant to be signed by a duly authorized officer and attested by its Secretary this 22nd day of November, 2002. 
  

	 NEOTHERAPEUTICS, INC. 
 
	 
	 By:
 	 	 /s/    JOHN L. MCMANUS          

	 Its:
 	 	 John L. McManus, V.P. Strategic
 

	  	 	 Planning & Finance
 

 
  
 
	 ATTEST:
 
	 
	 Name:
 	 	 /s/    CAROL GRUETTER        
 

	  	 	 Carol Gruetter
 
	 Title:
 	 	 Secretary
 

 
  
 [Corporate Seal] 

 
 -7- 

  
 ASSIGNMENT 
  
 FOR VALUE RECEIVED                      hereby sells, assigns and
transfers unto                              the foregoing thereby, and does irrevocably constitute and
appoint                             , attorney, to transfer said Warrant on the books of
NeoTherapeutics, Inc. 
  
 
	 
	 Dated:
 	 	 
	 	  	 	 Signature: 
 	 	 
	 	  
	 
	  	 	  	 	  	 	 Address:
 	 	 
	 	  

 
  
 PARTIAL ASSIGNMENT 
  
 FOR VALUE RECEIVED
                     hereby sells, assigns and transfers unto
                     the right to purchase             shares of the Common
Stock of NeoTherapeutics, Inc. covered by the foregoing Warrant, and a proportionate part of said Warrant and the rights evidenced thereby, and does irrevocably constitute and appoint
                , attorney, to transfer that part of said Warrant on the books of NeoTherapeutics, Inc. 
  

	 
	 Dated:
 	 	 
	 	  	 	 Signature: 
 	 	 
	 	  
	 
	  	 	  	 	  	 	 Address:
 	 	 
	 	  

 

 
 -8- 

  
 SUBSCRIPTION FORM 
  
 The undersigned hereby irrevocably elects to exercise the right of purchase represented by the attached Warrant for, and to purchase thereunder, shares of the Common Stock
of NeoTherapeutics, Inc., as provided for in Section 1 thereof. 
  
 The undersigned herewith makes payment for such
shares in full at the price per share provided by such Warrant in the following manner (please check the type or types of payment and indicate the portion of the aggregate payment to be paid by each type of payment): 
  
              exercise for cash as provided in Section 1 (a) of such
Warrant. 
  
              exercise by surrender of
such Warrant (or a portion thereof) in accordance with Section l (b) of such Warrant. 
  
 The undersigned
acknowledges that it has reviewed the representations and warranties contained in Section 3(b) of the Settlement Agreement (as defined in the Warrant) and by its signature below hereby makes such representations and warranties to NeoTherapeutics,
Inc., as of the date hereof and, if the undersigned is not Oppenheimer Wolff & Donnelly LLP, references to “Oppenheimer Wolff & Donnelly LLP” in such representations and warranties shall refer to the undersigned. 

 
 Please issue a certificate or certificates for such shares in the name of, and pay any cash for any fractional share to:

  
 
	 Name                                    
                                        
                               
 
	 
	 (Please Print Name, Address and Social Security No. or Taxpayer Identification No.)
 
	 
	 Address                                    
                                        
                           
  
  
                                      
                                        
                                        
 
 
	 
	 Social Security No. or
 Taxpayer Identification
No.                                       
                           
 
	 
	 Signature                                    
                                        
                        
 
	 
	 NOTE:
 	 	 The above signature should correspond exactly with
 the name on the first page of such
Warrant or with
 the name of the assignee appearing in the assignment
 form attached to the
Warrant.
 

 
  
 And if such number of shares shall not be all the shares
purchasable under the attached Warrant, a new Warrant is to be issued in the name of said undersigned for the balance remaining of the shares purchasable thereunder and delivered to the address set forth above. 

 
 -9-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}]]